S. 2236 (112th): Advancing Breakthrough Therapies for Patients Act of 2012

Introduced:

Mar 26, 2012
112th Congress, 2011–2013

Status:
Died in a previous Congress

This bill was introduced on March 26, 2012, in a previous session of Congress, but was not enacted.

Sponsor:

Michael Bennet

Senior Senator from Colorado

Democrat

Text:

Read Text »
Last Updated: Mar 26, 2012
Length: 8 pages

About the bill

Full Title

A bill to provide for the expedited development and evaluation of drugs designated as breakthrough drugs.

Read CRS summary >

Related Bills

Legislative action may be ocurring on one of these bills in lieu of or in parallel to action on this bill.

S. 3187 (Related)
Food and Drug Administration Safety and Innovation Act

Enacted — Signed by the President
Jul 9, 2012

S. 2516 (Related)
Food and Drug Administration Safety and Innovation Act

Reported by Committee
Last Action: May 7, 2012

What is a bill?

The “S.” in “S. 2236” means this is a Senate bill in the United States Congress. A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

The bill’s title was written by its sponsor.

History

Introduced
Mar 26, 2012

Details

Cosponsors
2 cosponsors (2R) (show)
Committee Assignments

The committee chair determines whether a bill will move past the committee stage.

Votes

There have been no votes related to this bill.

Links & tools

Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.

Citation

Click a format for a citation suggestion: